AIM 102

Drug Profile

AIM 102

Alternative Names: AIM-102

Latest Information Update: 30 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIM Therapeutics
  • Class Anti-inflammatories; Antiasthmatics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Mar 2013 AIM Therapeutics completes phase II trial in Asthma (NCT01501942)
  • 25 Oct 2012 AIM 102 is available for licensing after the completion of phase IIa trials.
  • 22 Oct 2012 Phase-II clinical trials in Asthma in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top